Scholars@Duke
Rebecca A Previs

Rebecca A Previs

Adjunct Assistant Professor in the Department of Obstetrics and Gynecology
Obstetrics and Gynecology, Gynecologic Oncology
rebecca.previs@duke.edu
Division of Gynecologic Oncolo, DUMC Box 3079, Durham, NC 27710
Manage Profile
Embed Profile Data

Selected Publications

Data from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <div>Abstract<p>Triple-negative breast cancers (TNBCs) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early stage localized TNBC, the rate of distant recurrence remains h ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Data from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <div>Abstract<p>Triple-negative breast cancers (TNBCs) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early stage localized TNBC, the rate of distant recurrence remains h ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer.

Journal Article Neoplasia · September 13, 2024 Single agent immune checkpoint inhibitors have been ineffective for patients with advanced stage and recurrent high grade serous ovarian cancer (HGSOC). Using pre-clinical models of HGSOC, we evaluated the anti-tumor and immune stimulatory effects of an on ... Full text Link to item Cite

Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer.

Journal Article Cancer Res Commun · March 18, 2024 UNLABELLED: This study investigated the association between health care access (HCA) dimensions and racial disparities in end-of-life (EOL) care quality among non-Hispanic Black (NHB), non-Hispanic White (NHW), and Hispanic patients with ovarian cancer. Th ... Full text Link to item Cite

TABLE 2 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Estimates of the associations between HCA dimensions, patient race and ethnicity, and EOL care quality outcomes on entire study cohort (<i>N</i> = 4,646), subcohort of patients that died from ovarian cancer (<i>N</i&gt ... Full text Cite

TABLE 1 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Baseline characteristics of patients with ovarian cancer who died during study follow-up stratified by race and ethnicity (<i>N</i> = 4,646)</p> ... Full text Cite

Supplementary Table 5 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Relative risk ratio (RR) for receipt of any chemotherapy within 14 days of death with interaction term between accessibility score and patient race</p> ... Full text Cite

TABLE 1 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Baseline characteristics of patients with ovarian cancer who died during study follow-up stratified by race and ethnicity (<i>N</i> = 4,646)</p> ... Full text Cite

FIGURE 1 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Participant flowchart for NHB, Hispanic and NHW patients with ovarian cancer, SEER-Medicare 2008–2015. Percentage of NHB patients presented for sensitivity purposes.</p> ... Full text Cite

Data from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <div>Abstract<p>Triple-negative breast cancers (TNBCs) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early stage localized TNBC, the rate of distant recurrence remains h ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Data from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <div>Abstract<p>Triple-negative breast cancers (TNBCs) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early stage localized TNBC, the rate of distant recurrence remains h ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer.

Journal Article Neoplasia · September 13, 2024 Single agent immune checkpoint inhibitors have been ineffective for patients with advanced stage and recurrent high grade serous ovarian cancer (HGSOC). Using pre-clinical models of HGSOC, we evaluated the anti-tumor and immune stimulatory effects of an on ... Full text Link to item Cite

Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer.

Journal Article Cancer Res Commun · March 18, 2024 UNLABELLED: This study investigated the association between health care access (HCA) dimensions and racial disparities in end-of-life (EOL) care quality among non-Hispanic Black (NHB), non-Hispanic White (NHW), and Hispanic patients with ovarian cancer. Th ... Full text Link to item Cite

TABLE 2 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Estimates of the associations between HCA dimensions, patient race and ethnicity, and EOL care quality outcomes on entire study cohort (<i>N</i> = 4,646), subcohort of patients that died from ovarian cancer (<i>N</i&gt ... Full text Cite

TABLE 1 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Baseline characteristics of patients with ovarian cancer who died during study follow-up stratified by race and ethnicity (<i>N</i> = 4,646)</p> ... Full text Cite

Supplementary Table 5 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Relative risk ratio (RR) for receipt of any chemotherapy within 14 days of death with interaction term between accessibility score and patient race</p> ... Full text Cite

TABLE 1 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Baseline characteristics of patients with ovarian cancer who died during study follow-up stratified by race and ethnicity (<i>N</i> = 4,646)</p> ... Full text Cite

FIGURE 1 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Participant flowchart for NHB, Hispanic and NHW patients with ovarian cancer, SEER-Medicare 2008–2015. Percentage of NHB patients presented for sensitivity purposes.</p> ... Full text Cite

TABLE 3 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Adjusted count ratio estimates of the associations between HCA dimensions, patient race and ethnicity, and counts of EOL care quality outcomes as count ratios, from fully-adjusted<a href="#tb3fn1" target="_blank"><sup>a</sup ... Full text Cite

Supplementary Table 1 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Patient, census tract, and regional level variables measuring dimensions of healthcare affordability, availability and accessibility</p> ... Full text Cite

TABLE 3 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Adjusted count ratio estimates of the associations between HCA dimensions, patient race and ethnicity, and counts of EOL care quality outcomes as count ratios, from fully-adjusted<a href="#tb3fn1" target="_blank"><sup>a</sup ... Full text Cite

Supplementary Table 4 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Relative risk ratio estimates of the associations between HCA dimensions, patient race/ethnicity, and EOL care quality outcomes</p> ... Full text Cite

Supplementary Table 5 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Relative risk ratio (RR) for receipt of any chemotherapy within 14 days of death with interaction term between accessibility score and patient race</p> ... Full text Cite

Data from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <div>Abstract<p>This study investigated the association between health care access (HCA) dimensions and racial disparities in end-of-life (EOL) care quality among non-Hispanic Black (NHB), non-Hispanic White (NHW), and Hispanic patients ... Full text Cite

TABLE 2 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Estimates of the associations between HCA dimensions, patient race and ethnicity, and EOL care quality outcomes on entire study cohort (<i>N</i> = 4,646), subcohort of patients that died from ovarian cancer (<i>N</i&gt ... Full text Cite

Supplementary Table 4 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Relative risk ratio estimates of the associations between HCA dimensions, patient race/ethnicity, and EOL care quality outcomes</p> ... Full text Cite

Data from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <div>Abstract<p>This study investigated the association between health care access (HCA) dimensions and racial disparities in end-of-life (EOL) care quality among non-Hispanic Black (NHB), non-Hispanic White (NHW), and Hispanic patients ... Full text Cite

FIGURE 1 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Participant flowchart for NHB, Hispanic and NHW patients with ovarian cancer, SEER-Medicare 2008–2015. Percentage of NHB patients presented for sensitivity purposes.</p> ... Full text Cite

FIGURE 2 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>EOL care quality outcomes by patient race and ethnicity (<i>N</i> = 4,646). ICU stay and ER visit outcomes not shown due to cell suppression rules. Outcomes that differ by patient race/ethnicity (<i>χ</i><sup> ... Full text Cite

FIGURE 2 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>EOL care quality outcomes by patient race and ethnicity (<i>N</i> = 4,646). ICU stay and ER visit outcomes not shown due to cell suppression rules. Outcomes that differ by patient race/ethnicity (<i>χ</i><sup> ... Full text Cite

Supplementary Table 1 from Health Care Access Dimensions and Racial Disparities in End-of-Life Care Quality among Patients with Ovarian Cancer

Other · March 18, 2024 <p>Patient, census tract, and regional level variables measuring dimensions of healthcare affordability, availability and accessibility</p> ... Full text Cite

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.

Journal Article Vaccines (Basel) · November 16, 2023 Significant progress has been achieved in the realm of therapeutic interventions for multiple myeloma (MM), leading to transformative shifts in its clinical management. While conventional modalities such as surgery, radiotherapy, and chemotherapy have impr ... Full text Link to item Cite

Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis.

Journal Article Cancer Res · September 1, 2023 UNLABELLED: Triple-negative breast cancers (TNBC) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early-stage localized TNBC, the rate of distant recurrence remains high, and long-term surviv ... Full text Link to item Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · September 1, 2023 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · September 1, 2023 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

Data from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Other · September 1, 2023 <div>Abstract<p>Triple-negative breast cancers (TNBC) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early-stage localized TNBC, the rate of distant recurrence remains hi ... Full text Cite

RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers.

Journal Article J Mol Diagn · July 2023 NRG1 gene fusions are rare, therapeutically relevant, oncogenic drivers that occur across solid tumor types. To understand the landscape of NRG1 gene fusions, 4397 solid tumor formalin-fixed, paraffin-embedded samples consecutively tested by comprehensive ... Full text Link to item Cite

Validation of the Labcorp Plasma Focus Test to Facilitate Precision Oncology Through Cell-Free DNA Genomic Profiling of Solid Tumors.

Journal Article J Mol Diagn · July 2023 Genomic profiling is critical for precision oncology to guide treatment decisions. Liquid biopsy testing is a complementary approach to tissue testing, particularly when tissue is not readily available. The Labcorp Plasma Focus test is a circulating cell-f ... Full text Link to item Cite

Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification.

Journal Article J Clin Oncol · March 20, 2023 PURPOSE: Preclinical cancer models harboring CCNE1 amplification were more sensitive to adavosertib treatment, a WEE1 kinase inhibitor, than models without amplification. Thus, we conducted this phase II study to assess the antitumor activity of adavoserti ... Full text Link to item Cite

Diversity and transparency in gynecologic oncology clinical trials.

Conference Cancer Causes Control · February 2023 PURPOSE: Clinical trials advance the standard of care for patients. Patients enrolled in trials should represent the population who would benefit from the intervention in clinical practice. The aim of this study was to assess whether clinical trials enroll ... Full text Link to item Cite

Association of Genomic Instability Score, Tumor Mutational Burden, and Tumor-Infiltrating Lymphocytes as Biomarkers in Uterine Serous Carcinoma.

Journal Article Cancers (Basel) · January 15, 2023 Background: Uterine serous carcinomas represent 10% of uterine carcinomas but account for nearly 40% of deaths from the disease. Improved molecular characterization of these tumors is instrumental in guiding targeted treatment and improving outcomes. This ... Full text Link to item Cite

Healthcare Access Domains Mediate Racial Disparities in Ovarian Cancer Treatment Quality in a US Patient Cohort: A Structural Equation Modelling Analysis.

Journal Article Cancer Epidemiol Biomarkers Prev · January 9, 2023 BACKGROUND: Ovarian cancer survival disparities have persisted for decades, driven by lack of access to quality treatment. We conducted structural equation modeling (SEM) to define latent variables representing three healthcare access (HCA) domains: afford ... Full text Link to item Cite

BAP1 Tumor Predisposition Syndrome Presenting as a Recurrent Ovarian Sex Cord-Stromal Tumor.

Journal Article Int J Gynecol Pathol · January 1, 2023 The BRCA1-associated protein 1 ( BAP1 ) gene encodes a tumor suppressor that functions as a ubiquitin hydrolase involved in DNA damage repair. BAP1 germline mutations are associated with increased risk of multiple solid malignancies, including mesothelioma ... Full text Link to item Cite

Race, Affordability and Utilization of Supportive Care in Ovarian Cancer Patients.

Journal Article J Pain Symptom Manage · December 2022 OBJECTIVE: Lack of access to supportive care (SC) among cancer patients have been well documented. However, the role of affordability in this disparity among ovarian cancer (OC) patients remain poorly understood. METHODS: Patients with OC between 2008 and ... Full text Link to item Cite

Stress hormones are associated with inflammatory cytokines and attenuation of T-cell function in the ascites from patients with high grade serous ovarian cancer.

Journal Article Brain Behav Immun Health · December 2022 Mounting evidence suggests that chronic stress and subsequent distress can promote ovarian cancer progression. These altered psychological states have been linked to sustained release of stress hormones, activation of the β-adrenergic receptors in ovarian ... Full text Link to item Cite

Telemedicine and gynecologic oncology: caring for patients remotely during a global pandemic

Conference AJOG Global Reports · November 1, 2022 BACKGROUND: Telemedicine uses technology to deliver medical care remotely and has been shown to provide similar patient satisfaction and care outcomes compared with in-person visits. OBJECTIVE: This study aimed to assess the gynecologic oncology patient te ... Full text Cite

Healthcare Access Dimensions and Guideline-Concordant Ovarian Cancer Treatment: SEER-Medicare Analysis of the ORCHiD Study.

Journal Article J Natl Compr Canc Netw · November 2022 BACKGROUND: Racial disparities exist in receipt of guideline-concordant treatment of ovarian cancer (OC). However, few studies have evaluated how various dimensions of healthcare access (HCA) contribute to these disparities. METHODS: We analyzed data from ... Full text Link to item Cite

Telemedicine and gynecologic oncology: caring for patients remotely during a global pandemic.

Journal Article AJOG Glob Rep · November 2022 BACKGROUND: Telemedicine uses technology to deliver medical care remotely and has been shown to provide similar patient satisfaction and care outcomes compared with in-person visits. OBJECTIVE: This study aimed to assess the gynecologic oncology patient te ... Full text Link to item Cite

Using genetically encoded fluorescent biosensors to interrogate ovarian cancer metabolism.

Journal Article J Ovarian Res · October 20, 2022 BACKGROUND: Epithelial ovarian cancer (OC) is the most lethal gynecological malignancy and patients present with significant metastatic burden, particularly to the adipose-rich microenvironment of the omentum. Recent evidence has highlighted the importance ... Full text Link to item Cite

Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.

Journal Article Cancers (Basel) · August 30, 2022 Despite advances in surgery and targeted therapies, the prognosis for women with high-grade serous ovarian cancer remains poor. Moreover, unlike other cancers, immunotherapy has minimally impacted outcomes in patients with ovarian cancer. Progress in this ... Full text Open Access Link to item Cite

Associations of Healthcare Affordability, Availability, and Accessibility with Quality Treatment Metrics in Patients with Ovarian Cancer.

Journal Article Cancer Epidemiol Biomarkers Prev · July 1, 2022 BACKGROUND: Differential access to quality care is associated with racial disparities in ovarian cancer survival. Few studies have examined the association of multiple healthcare access (HCA) dimensions with racial disparities in quality treatment metrics, ... Full text Link to item Cite

G6PD inhibition sensitizes ovarian cancer cells to oxidative stress in the metastatic omental microenvironment.

Journal Article Cell Rep · June 28, 2022 Ovarian cancer (OC) is the most lethal gynecological malignancy, with aggressive metastatic disease responsible for the majority of OC-related deaths. In particular, OC tumors preferentially metastasize to and proliferate rapidly in the omentum. Here, we s ... Full text Link to item Cite

Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database.

Journal Article Gynecol Oncol · May 2022 OBJECTIVE: To assess, using a national surgical outcomes database, the association of various malnutrition definitions with post-operative morbidity in three gynecologic malignancies. METHODS: Patients undergoing resection of ovarian, uterine, or cervical ... Full text Link to item Cite

Endometrial cancer

Chapter · January 1, 2022 The prior dichotomous classification of endometrial cancer into high and low risk subtypes based primarily on histology has been shown to be inadequate in predicting outcome and treatment response. More nuanced molecular categorization of these cancers pro ... Full text Cite

Endometrial Adenocarcinomas With No Specific Molecular Profile: Morphologic Features and Molecular Alterations of "Copy-number Low" Tumors.

Journal Article Int J Gynecol Pathol · November 1, 2021 The study evaluated morphologic patterns, mutational profiles, and β-catenin immunohistochemistry (IHC) in copy-number low (CNL) endometrial adenocarcinomas (EAs). CNL EAs (n=19) with next-generation or whole genome sequencing results and available tissue ... Full text Link to item Cite

Neoadjuvant chemotherapy for advanced stage endometrial cancer: A systematic review.

Journal Article Gynecol Oncol Rep · November 2021 OBJECTIVE: While primary cytoreductive surgery (PCS) is considered the standard of care for women who present with stage IV endometrial cancer, neoadjuvant chemotherapy (NACT) followed by interval cytoreductive surgery (ICS) has emerged as an alternative t ... Full text Link to item Cite

Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis.

Journal Article Am J Obstet Gynecol · September 2021 OBJECTIVE: Endometrial cancer uncommonly presents at an advanced stage and little prospective evidence exists to guide the management thereof. We aimed to summarize the evidence about primary cytoreductive surgery in the treatment of advanced stage endomet ... Full text Link to item Cite

Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer.

Journal Article Gynecol Oncol · September 2021 OBJECTIVE: Neoadjuvant chemotherapy (NACT) has emerged as an alternative to primary cytoreductive surgery (PCS) for stage IV uterine cancer. We examined utilization, perioperative outcomes and survival for NACT and PCS for stage IV uterine cancer. METHODS: ... Full text Link to item Cite

Optimizing ethyl cellulose-ethanol delivery towards enabling ablation of cervical dysplasia.

Journal Article Sci Rep · August 19, 2021 In low-income countries, up to 80% of women diagnosed with cervical dysplasia do not return for follow-up care, primarily due to treatment being inaccessible. Here, we describe development of a low-cost, portable treatment suitable for such settings. It is ... Full text Link to item Cite

Adnexal Masses in Pregnancy.

Journal Article Obstet Gynecol Surv · July 2021 IMPORTANCE: Adnexal masses are identified in approximately 0.05% to 2.4% of pregnancies, and more recent data note a higher incidence due to widespread use of antenatal ultrasound. Whereas most adnexal masses are benign, approximately 1% to 6% are malignan ... Full text Link to item Cite

Molecular Classification to Prognosticate Response in Medically Managed Endometrial Cancers and Endometrial Intraepithelial Neoplasia.

Journal Article Cancers (Basel) · June 7, 2021 BACKGROUND: The aim of this study was to evaluate whether molecular classification prognosticates treatment response in women with endometrial cancers and endometrial intraepithelial neoplasia (EIN) treated with levonorgestrel intrauterine system (LNG-IUS) ... Full text Link to item Cite

Health Care Access Measures and Palliative Care Use by Race/Ethnicity among Metastatic Gynecological Cancer Patients in the United States.

Journal Article Int J Environ Res Public Health · June 4, 2021 Palliative care improves quality-of-life and extends survival, however, is underutilized among gynecological cancer patients in the United States (U.S.). Our objective was to evaluate associations between healthcare access (HCA) measures and palliative car ... Full text Link to item Cite

SARS-CoV-2 vaccination in gynecologic oncology

Journal Article European Journal of Gynaecological Oncology · April 15, 2021 Full text Cite

Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer.

Journal Article Int J Gynecol Cancer · February 2021 INTRODUCTION: The surgical approach for interval debulking surgery after neoadjuvant chemotherapy has been extrapolated from primary tumor reductive surgery for high-grade ovarian cancer. The study objective was to compare pathologic distribution of malign ... Full text Link to item Cite

Racial and ethnic disparities in palliative care utilization among gynecological cancer patients.

Journal Article Gynecol Oncol · February 2021 BACKGROUND: Palliative care (PC) is recommended for gynecological cancer patients to improve survival and quality-of-life. Our objective was to evaluate racial/ethnic disparities in PC utilization among patients with metastatic gynecologic cancer. METHODS: ... Full text Link to item Cite

Racial disparities in palliative care utilization among metastatic gynecological cancer patients living at last follow-up: An analysis of the National Cancer Data Base.

Journal Article Data Brief · February 2021 The National Comprehensive Cancer Network recommends palliative care should be integrated in to cancer care starting from cancer diagnosis. However, traditionally palliative care is prioritized for cancer patients at the end-of-life. In our main article ti ... Full text Link to item Cite

Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative.

Journal Article Gynecol Oncol · January 2021 OBJECTIVE: To determine the feasibility and effectiveness of a quality improvement initiative (QI) to adopt universal screening for Lynch syndrome in uterine cancer patients at an institution that previously employed age-based screening. METHODS: Prior to ... Full text Link to item Cite

Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers.

Journal Article Target Oncol · January 2021 BACKGROUND: Recent advances in next-generation sequencing have allowed for an increase in molecular tumor profiling. OBJECTIVE: We sought to assess the actionability and clinical utilization of molecular tumor profiling results obtained via Foundation Medi ... Full text Link to item Cite

Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices.

Journal Article Int J Gynecol Cancer · October 2020 OBJECTIVE: Limited information exists regarding risk reduction strategies for women with moderate and low penetrance ovarian cancer susceptibility mutations. We sought to assess current risk reduction practice patterns for carriers of these mutations throu ... Full text Link to item Cite

Differential expression of immune related genes in high-grade ovarian serous carcinoma.

Journal Article Gynecol Oncol · March 2020 OBJECTIVE: To identify novel immunologic targets and biomarkers associated with overall survival (OS) in high-grade serous ovarian cancer (HGSC). METHODS: In this retrospective study, microarray data from 51 HGSC specimens were analyzed (Affymetrix HG-U133 ... Full text Link to item Cite

The MARBLE Study Protocol: Modulating ApoE Signaling to Reduce Brain Inflammation, DeLirium, and PostopErative Cognitive Dysfunction.

Journal Article J Alzheimers Dis · 2020 BACKGROUND: Perioperative neurocognitive disorders (PND) are common complications in older adults associated with increased 1-year mortality and long-term cognitive decline. One risk factor for worsened long-term postoperative cognitive trajectory is the A ... Full text Open Access Link to item Cite

Becoming a surgeon-scientist: my transition from fellowship to faculty.

Journal Article Clin Adv Hematol Oncol · December 2019 Link to item Cite

Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.

Journal Article Gynecol Oncol · August 2019 OBJECTIVE: To evaluate clinicopathologic factors and adjuvant treatment effects on recurrence free (RFS) and overall survival (OS) in early stage uterine clear cell carcinoma (UCCC). METHODS: Our retrospective review included central pathology confirmed st ... Full text Link to item Cite

The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction.

Journal Article J Am Geriatr Soc · April 2019 BACKGROUND/OBJECTIVES: Every year, up to 40% of the more than 16 million older Americans who undergo anesthesia/surgery develop postoperative cognitive dysfunction (POCD) or delirium. Each of these distinct syndromes is associated with decreased quality of ... Full text Open Access Link to item Cite

Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.

Journal Article Gynecol Oncol · March 2019 OBJECTIVES: To evaluate surgical complexity scores (SCS) and minimally invasive surgery (MIS) at interval debulking surgery (IDS) in advanced epithelial ovarian cancer (EOC) patients receiving neoadjuvant chemotherapy (NACT). METHODS: A multi-institutional ... Full text Link to item Cite

Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management.

Journal Article Obstet Gynecol Clin North Am · March 2019 Ovarian cancer treatment continues to evolve. Despite aggressive surgery and chemotherapy, most women will ultimately die from disease. Improvement in disease control are due to the incorporation of molecular targeted agents and the adoption of maintenance ... Full text Link to item Cite

Prognostic factors impacting survival in early stage uterine carcinosarcoma.

Journal Article Gynecol Oncol · January 2019 OBJECTIVE: Evaluate the impact of clinicopathologic characteristics and adjuvant treatment on survival outcomes in early stage uterine carcinosarcoma patients. METHODS: We performed a retrospective cohort study of women with stage I or II uterine carcinosa ... Full text Link to item Cite

Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.

Journal Article Cancer Res · June 15, 2018 Mounting clinical and preclinical evidence supports a key role for sustained adrenergic signaling in the tumor microenvironment as a driver of tumor growth and progression. However, the mechanisms by which adrenergic neurotransmitters are delivered to the ... Full text Link to item Cite

Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer.

Journal Article Mol Cancer Ther · February 2018 Although progesterone receptor (PR)-targeted therapies are modestly active in patients with uterine cancer, their underlying molecular mechanisms are not well understood. The clinical use of such therapies is limited because of the lack of biomarkers that ... Full text Link to item Cite

Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.

Journal Article Clin Cancer Res · November 15, 2017 Purpose: VEGF-targeted therapies have modest efficacy in cancer patients, but acquired resistance is common. The mechanisms underlying such resistance are poorly understood.Experimental Design: To evaluate the potential role of immune cells in the developm ... Full text Link to item Cite

Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy.

Journal Article Oncotarget · November 14, 2017 Anti-angiogenesis therapy has shown clinical benefit in patients with high-grade serous ovarian cancer (HGSC), but adaptive resistance rapidly emerges. Thus, approaches to overcome such resistance are needed. We developed the setting of adaptive resistance ... Full text Link to item Cite

Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.

Journal Article J Natl Cancer Inst · July 1, 2017 BACKGROUND: The PI3K/AKT/P70S6K pathway is an attractive therapeutic target in ovarian and uterine malignancies because of its high rate of deregulation and key roles in tumor growth. Here, we examined the biological effects of MSC2363318A, which is a nove ... Full text Link to item Cite

Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy

Journal Article Oncotarget · January 1, 2017 Anti-angiogenesis therapy has shown clinical benefit in patients with highgrade serous ovarian cancer (HGSC), but adaptive resistance rapidly emerges. Thus, approaches to overcome such resistance are needed. We developed the setting of adaptive resistance ... Full text Cite

Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.

Journal Article Mol Cancer Ther · December 2016 To determine the efficacy of a novel and safer (for gastrointestinal tract) aspirin (aspirin-PC) in preclinical models of ovarian cancer, in vitro dose-response studies were performed to compare the growth-inhibitory effect of aspirin-PC versus aspirin on ... Full text Link to item Cite

The rise of genomic profiling in ovarian cancer.

Journal Article Expert Rev Mol Diagn · December 2016 Next-generation sequencing and advances in 'omics technology have rapidly increased our understanding of the molecular landscape of epithelial ovarian cancers. Areas covered: Once characterized only by histologic appearance and clinical behavior, we now un ... Full text Link to item Cite

Cesarean delivery among women with prolonged labor induction.

Journal Article J Perinat Med · October 1, 2016 OBJECTIVE: The objective of this study was to determine characteristics associated with cesarean delivery among women with labor induction lasting over 24 h. STUDY DESIGN: Women with live singleton pregnancies without prior cesarean delivery undergoing a l ... Full text Link to item Cite

Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression.

Journal Article Oncogene · August 18, 2016 MicroRNAs (miRNAs) are small RNA molecules that affect cellular processes by controlling gene expression. Recent studies have shown that hypoxia downregulates Drosha and Dicer, key enzymes in miRNA biogenesis, causing a decreased pool of miRNAs in cancer a ... Full text Link to item Cite

Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer.

Journal Article J Med Imaging (Bellingham) · July 2016 Silicon-based nanoparticles are ideally suited for use as biomedical imaging agents due to their biocompatibility, biodegradability, and simple surface chemistry that facilitates drug loading and targeting. A method of hyperpolarizing silicon particles usi ... Full text Link to item Cite

Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.

Journal Article Mol Cancer Ther · June 2016 Delta-like ligand 4 (Dll4), one of the Notch ligands, is overexpressed in ovarian cancer, especially in tumors resistant to anti-VEGF therapy. Here, we examined the biologic effects of dual anti-Dll4 and anti-VEGF therapy in ovarian cancer models. Using Dl ... Full text Link to item Cite

Sustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.

Journal Article Oncogene · May 5, 2016 Adrenergic stimulation adversely affects tumor growth and metastasis, but the underlying mechanisms are not well understood. Here, we uncovered a novel mechanism by which catecholamines induce inflammation by increasing prostaglandin E2 (PGE2) levels in ov ... Full text Link to item Cite

Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.

Journal Article Clin Cancer Res · April 1, 2016 PURPOSE: Chronic adrenergic activation has been shown to associate with adverse clinical outcomes in cancer patients, but the underlying mechanisms are not well understood. The focus of the current study was to determine the functional and biologic effects ... Full text Link to item Cite

Role of Increased n-acetylaspartate Levels in Cancer.

Journal Article J Natl Cancer Inst · January 26, 2016 BACKGROUND: The clinical and biological effects of metabolic alterations in cancer are not fully understood. METHODS: In high-grade serous ovarian cancer (HGSOC) samples (n = 101), over 170 metabolites were profiled and compared with normal ovarian tissues ... Full text Link to item Cite

Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.

Journal Article Cell Rep · December 22, 2015 Long noncoding RNAs (lncRNAs) significantly influence the development and regulation of genome expression in cells. Here, we demonstrate the role of lncRNA ceruloplasmin (NRCP) in cancer metabolism and elucidate functional effects leading to increased tumo ... Full text Link to item Cite

Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.

Journal Article Gynecol Oncol · December 2015 BACKGROUND: To compare the efficacy of chemotherapy (C) combined with bevacizumab (Bev) versus Bev alone in recurrent, heavily pretreated epithelial ovarian cancer (EOC). METHODS: A multicenter analysis of patients treated from 2004 to 2011 was performed. ... Full text Link to item Cite

Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.

Journal Article Mol Cancer Ther · December 2015 There is growing recognition of the important role of metronomic chemotherapy in cancer treatment. On the basis of their unique antiangiogenic effects, we tested the efficacy of nab-paclitaxel, which stimulates thrombospondin-1, and topotecan, which inhibi ... Full text Link to item Cite

Erythropoietin Stimulates Tumor Growth via EphB4.

Journal Article Cancer Cell · November 9, 2015 While recombinant human erythropoietin (rhEpo) has been widely used to treat anemia in cancer patients, concerns about its adverse effects on patient survival have emerged. A lack of correlation between expression of the canonical EpoR and rhEpo's effects ... Full text Link to item Cite

Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.

Journal Article Eur J Cancer · September 2015 BACKGROUND: We compared survival outcomes and risk of venous thromboembolism (VTE) among patients with advanced and early-stage ovarian clear cell carcinoma (OCCC) and serous ovarian carcinoma (SOC), as well as potential links with interleukin-6 (IL-6) lev ... Full text Link to item Cite

Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.

Journal Article Gynecol Oncol · August 2015 OBJECTIVE: Type I epithelial ovarian cancers (EOCs) are reported to be relatively chemoresistant. This study sought to compare pretreatment chemoresponse assays in Type I vs. Type II EOCs. STUDY DESIGN: 383 women with stage III-IV EOC enrolled in an observ ... Full text Link to item Cite

XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.

Journal Article Clin Cancer Res · July 15, 2015 PURPOSE: XPO1 inhibitors have shown promise for cancer treatment, and yet the underlying mechanisms for the antitumor effects are not well understood. In this study, we explored the usefulness of selective inhibitors of nuclear export (SINE) compounds that ... Full text Link to item Cite

PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.

Journal Article Mol Cancer Ther · June 2015 PTEN is known to be frequently mutated in uterine cancer and also dephosphorylates FAK. Here, we examined the impact of PTEN alterations on the response to treatment with a FAK inhibitor (GSK2256098). In vitro and in vivo therapeutic experiments were carri ... Full text Link to item Cite

Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.

Journal Article Clin Cancer Res · May 1, 2015 PURPOSE: Zoledronic acid is being increasingly recognized for its antitumor properties, but the underlying functions are not well understood. In this study, we hypothesized that zoledronic acid inhibits ovarian cancer angiogenesis preventing Rac1 activatio ... Full text Link to item Cite

Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer.

Journal Article Clin Cancer Res · March 1, 2015 Over 100 years have passed since the first observation of the notched wing phenotype in Drosophila melanogaster, and significant progress has been made to characterize the role of the Notch receptor, its ligands, downstream targets, and cross-talk with oth ... Full text Link to item Cite

Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth.

Journal Article Oncotarget · February 28, 2015 Increased adrenergic signaling facilitates tumor progression, but the underlying mechanisms remain poorly understood. We examined factors responsible for stress-mediated effects on monocyte/macrophage recruitment into the tumor microenvironment, and the re ... Full text Link to item Cite

Differential platelet levels affect response to taxane-based therapy in ovarian cancer.

Journal Article Clin Cancer Res · February 1, 2015 PURPOSE: We hypothesized that platelet levels during therapy could serve as a biomarker for response to therapy and that manipulation of platelet levels could impact responsiveness to chemotherapy. EXPERIMENTAL DESIGN: The medical records of patients with ... Full text Link to item Cite

Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.

Journal Article Clin Cancer Res · January 15, 2015 PURPOSE: Cancer cells are highly dependent on folate metabolism, making them susceptible to drugs that inhibit folate receptor activities. Targeting overexpressed folate receptor alpha (FRα) in cancer cells offers a therapeutic opportunity. We investigated ... Full text Link to item Cite

Notch3 pathway alterations in ovarian cancer.

Journal Article Cancer Res · June 15, 2014 The Notch pathway plays an important role in the growth of high-grade serous ovarian (HGS-OvCa) and other cancers, but its clinical and biologic mechanisms are not well understood. Here, we found that the Notch pathway alterations are prevalent and signifi ... Full text Link to item Cite

Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.

Journal Article Clin Cancer Res · May 15, 2014 PURPOSE: Platelet-derived growth factor receptor α (PDGFRα) expression is frequently observed in many kinds of cancer and is a candidate for therapeutic targeting. This preclinical study evaluated the biologic significance of PDGFRα and PDGFRα blockade (us ... Full text Link to item Cite

Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer.

Journal Article Int J Gynecol Cancer · May 2014 OBJECTIVE: The objective of this study was to evaluate prognostic risk factors for survival in women with low-grade serous epithelial ovarian cancer (LGSC). METHODS: A multicenter retrospective analysis of patients with LGSC was conducted. Potential epidem ... Full text Link to item Cite

2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.

Journal Article Nat Commun · March 12, 2014 Improving small interfering RNA (siRNA) efficacy in target cell populations remains a challenge to its clinical implementation. Here, we report a chemical modification, consisting of phosphorodithioate (PS2) and 2'-O-Methyl (2'-OMe) MePS2 on one nucleotide ... Full text Link to item Cite

A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.

Journal Article Gynecol Oncol · March 2014 OBJECTIVE: To develop a nomogram to predict overall survival (OS) in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. METHODS: A multicenter retrospective study was conducted. Potential prognostic variables included age; stage ... Full text Link to item Cite

Cystic fibrosis involving the cervix, mimicking a well-differentiated adenocarcinoma: a case report.

Journal Article Int J Gynecol Pathol · January 2014 We describe clinicopathologic and immunohistochemical features of an unusual case of cystic fibrosis manifesting in the cervix as a mass lesion, mimicking cervical adenocarcinoma. A 24-year-old nulligravida with cystic fibrosis developed heavy postcoital v ... Full text Link to item Cite